暂无数据
Vitrafy Life Sciences期权到期,简化了资本结构
Vitrafy Life Sciences 寻求在澳交所上市以进行新股发行
Vitrafy缩减超额认购的股票发行规模,以支持其增长计划
Ord Minnett 维持对 Vitrafy Life Sciences Ltd.(VFY)的买入评级。
Vitrafy Life Sciences Price Target Raised 75% to A$4.20/Share by Ord Minnett
Vitrafy Life Sciences Price Target Raised 72% to A$5.15/Share by Bell Potter